A5055885925- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Gallbladder and Bile Duct Disorders
- Cancer Treatment and Pharmacology
- Renal Transplantation Outcomes and Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- PARP inhibition in cancer therapy
- Herpesvirus Infections and Treatments
- T-cell and Retrovirus Studies
- Gastroesophageal reflux and treatments
- Pharmaceutical Practices and Patient Outcomes
- Gastrointestinal Bleeding Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
The University of Texas MD Anderson Cancer Center
2016-2025
Riga Technical College
2019
John Wiley & Sons (United States)
2016
Centre Hospitalier Universitaire Brugmann
1972-2015
International Society for Heart and Lung Transplantation
2011
National Heart Lung and Blood Institute
2011
European Society for Blood and Marrow Transplantation
2011
Clinique Saint Jean
1984
Leefmilieu Brussel
1972
Hemorrhagic cystitis is a common cause of morbidity after allogeneic stem cell transplantation, frequently associated with BK virus infection. We hypothesized that patients positive viruria before unrelated or mismatched related donor hematopoietic transplantation have higher incidence hemorrhagic cystitis.To test this hypothesis, we prospectively studied 209 (median age 49 years, range 19-71) hematologic malignancies who received bone marrow (n=78), peripheral blood (n=108) umbilical cord...
Abstract In this phase I/II clinical trial, we investigated the safety and efficacy of high doses mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation (HSCT). Three donor (1 × 10 5 –1 8 cells/kg/dose) were administered on days −2, +7, +28. Results compared an independent contemporaneously treated case-matched cohort 160 from CIBMTR database. After a median follow-up 24 months, 2-year...
Tacrolimus-associated posterior reversible encephalopathy syndrome (PRES) is a potential complication of allogeneic stem cell transplant (SCT). Due to the paucity information on management PRES in SCT patients receiving tacrolimus, more needed trends associated with incidence and characterize its management. A retrospective review was conducted tacrolimus for prevention graft versus host disease (GVHD) after who developed from September 2008 July 2011. Nineteen were identified. Altered...
Abstract Background Hematopoietic stem cell transplant ( HCT ) recipients are more susceptible to infections from vaccine‐preventable diseases than the general population. Despite development of international consensus guidelines addressing immunization after , studies have shown that deviations recommended practices commonly occur. Methods An anonymous survey aimed at determining awareness and attitudes toward vaccination was distributed our clinicians. In parallel, we retrospectively...
BACKGROUND More active high‐dose chemotherapy (HDC) regimens are needed for refractory lymphomas. The authors previously combined infusional gemcitabine with busulfan and melphalan (Gem/Bu/Mel) pursuing DNA damage repair inhibition. Subsequently, they Gem/Bu/Mel vorinostat, which facilitates access to DNA. resulting regimen was safe synergistic. However, vorinostat induced methyltransferase up‐regulation, could be preclinically abrogated by azacitidine, increasing tumor‐cell kill. Those...
We developed a new high-dose combination of infusional gemcitabine with busulfan and melphalan for lymphoid tumors. Gemcitabine dose was escalated by extending infusions at fixed rate 10 mg/m(2)/min in sequential cohorts, daily, 3-dose or 2-dose schedules. Each immediately preceded (adjusted targeting area under the curve 4,000 μM/min(-1)/day × 4 days) (60 mg/m(2)/day 2 days). enrolled 133 patients (80 Hodgkin lymphoma [HL], 46 non-Hodgkin [NHL], 7 myeloma), median 3 prior regimens; primary...
More active high-dose regimens are needed for refractory/poor-risk relapsed lymphomas. We previously developed a regimen of infusional gemcitabine/busulfan/melphalan, exploiting the synergistic interaction. Its encouraging activity in refractory lymphomas led us to further enhance its use as platform epigenetic modulation. observed increased cytotoxicity lymphoma cell lines when histone deacetylase inhibitor vorinostat was added which prompted clinically study this four-drug combination....
Cytomegalovirus (CMV) infection can increase the morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Because of a higher degree immunosuppression, haploidentical transplant recipients may be at an increased risk viral infections, particularly CMV. We retrospectively analyzed 86 HCT our institution to determine whether more intensified antiviral strategy would reduce incidence CMV reactivation compared with traditional prophylaxis regimen. According practice...
Purpose: Prevention or treatment of relapsed lymphoid malignancies after hematopoietic stem cell transplantation (HSCT) requires novel strategies. We hypothesized that antitumor-cell responses could be enhanced by the addition lenalidomide to cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab.Experimental Design: conducted a phase II investigator-initiated trial assess safety and activity ipilimumab in patients with allogeneic HSCT high-risk autologous HSCT. Patients received...
Objective: To report the case of a clinically significant drug interaction between intravenous busulfan and oral metronidazole observed through therapeutic monitoring (TDM). Case Summary: A 7-year-old boy with history myelodysplasia that progressed to acute myeloid leukemia received (TDM), clofarabine, thiotepa as pretransplant conditioning regimen for cord blood transplant. The patient day after test dose 0.5 mg/kg was administered. On first dose, TDM performed clearance significantly...
More active high-dose chemotherapy (HDC) regimens are needed for autologous stem-cell transplantation (ASCT) refractory lymphomas. Seeking HDC enhancement with a poly(ADP-ribose) polymerase (PARP) inhibitor, we observed marked synergy between olaparib and vorinostat/gemcitabine/busulfan/melphalan (GemBuMel) against lymphoma cell lines, mediated by inhibition of DNA damage repair. Our preclinical work led us to clinically study olaparib/vorinostat/GemBuMel ASCT. Patients ages 15-65 adequate...